Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors

被引:39
作者
Oh, Eun Hye [1 ]
Oh, Kyunghwan [1 ]
Han, Minkyu [2 ]
Seo, Hyungil [3 ]
Chang, Kiju [3 ]
Lee, Sun-Ho [3 ]
Kim, Gwang-Un [3 ]
Song, Eun Mi [3 ]
Seo, Myeongsook [3 ]
Lee, Ho-Su [4 ]
Hwang, Sung Wook [3 ,5 ]
Park, Sang Hyoung [3 ,5 ]
Yang, Dong-Hoon [3 ]
Kim, Kyung-Jo [3 ,5 ]
Byeon, Jeong-Sik [3 ]
Myung, Seung-Jae [3 ]
Yang, Suk-Kyun [3 ,5 ]
Ye, Byong Duk [3 ,5 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Dept Clin Epidemiol & Biostat, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Hlth Screening & Promot Ctr, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Ctr Inflammatory Bowel Dis, Seoul, South Korea
关键词
EARLY COMBINED IMMUNOSUPPRESSION; RANDOMIZED CONTROLLED-TRIAL; INFLAMMATORY-BOWEL-DISEASE; HOSPITAL-BASED COHORT; CONVENTIONAL MANAGEMENT; COMBINATION THERAPY; CERTOLIZUMAB PEGOL; INFLIXIMAB; AZATHIOPRINE; MAINTENANCE;
D O I
10.1371/journal.pone.0177479
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Although early treatment of Crohn's disease (CD) patients with anti-tumor necrosis factor (TNF) agents or immunomodulators (IMs) may improve long-term outcomes, especially those with poor prognostic factors, their effectiveness in Asians remains unclear. In this study, Korean patients with CD naive to both intestinal surgery and intestinal complications, and with at least two risk factors for progression (diagnosis at age <40 years, systemic corticosteroid treatment <3 months after diagnosis, and perianal fistula at diagnosis) were retrospectively analyzed. Patients were classified into those who started anti-TNFs, or IMs but not anti-TNFs, within 2 years of diagnosis, and those who started anti-TNFs and/or IMs later. Their probabilities of intestinal surgery and intestinal complications were compared. A total of 670 patients were enrolled, 79 in the early anti-TNF, 286 in the early IM, and 305 in the late treatment group. Kaplan-Meier analysis with the log-rank test showed that from starting anti-TNFs/IMs, times to intestinal surgery (P < 0.001), stricturing complications (P = 0.002), and penetrating complications (P < 0.001) were significantly longer in the early anti-TNF/IM groups than in the late treatment group. Multivariate Cox regression analysis showed that, from starting anti-TNFs/IMs, late anti-TNF/IM treatment was independently associated with higher risks of intestinal surgery (adjusted hazard ratio [aHR] 2.321, 95% confidence interval [CI] 1.503-3.584, P < 0.001), behavioral progression (aHR 2.001, 95% CI 1.449-2.763, P < 0.001), stricturing complications (aHR 1.736, 95% CI 1.209-2.493, P = 0.003), and penetrating complications (aHR 3.315, 95% CI 2.094-5.249, P < 0.001) than early treatment. In conclusion, treatment of Asian CD patients having poor prognostic factors with anti-TNFs/IMs within 2 years of diagnosis is associated with better clinical outcomes than later treatment.
引用
收藏
页数:17
相关论文
共 46 条
[1]   Can Colonoscopy Reduce the Risk of Colon Cancer and Mortality in Patients With Inflammatory Bowel Disease? [J].
Aberra, Faten N. ;
Osterman, Mark T. ;
Lewis, James D. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (09) :1702-1703
[2]   Treatment algorithms in Crohn's - Up, down or something else? [J].
Antunes, Ophelie ;
Filippi, Jerome ;
Hebuterne, Xavier ;
Peyrin-Biroulet, Laurent .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (03) :473-483
[3]   Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease [J].
Baert, Filip ;
Moortgat, Liesbeth ;
Van Assche, Gert ;
Caenepeel, Philip ;
Vergauwe, Philippe ;
De Vos, Martine ;
Stokkers, Pieter ;
Hommes, Daniel ;
Rutgeerts, Paul ;
Vermeire, Severine ;
D'Haens, Geert .
GASTROENTEROLOGY, 2010, 138 (02) :463-468
[4]   Crohn's disease [J].
Baumgart, Daniel C. ;
Sandborn, William J. .
LANCET, 2012, 380 (9853) :1590-1605
[5]   Predictors of Crohn's disease [J].
Beaugerie, L ;
Seksik, P ;
Nion-Larmurier, I ;
Gendre, JP ;
Cosnes, J .
GASTROENTEROLOGY, 2006, 130 (03) :650-656
[6]   Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].
Colombel, Jean Frederic ;
Sandborn, William J. ;
Reinisch, Walter ;
Mantzaris, Gerassimos J. ;
Kornbluth, Asher ;
Rachmilewitz, Daniel ;
Lichtiger, Simon ;
D'Haens, Geert ;
Diamond, Robert H. ;
Broussard, Delma L. ;
Tang, Kezhen L. ;
van der Woude, C. Janneke ;
Rutgeerts, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395
[7]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[8]   Adalimumab Induces Deep Remission in Patients With Crohn's Disease [J].
Colombel, Jean-Frederic ;
Rutgeerts, Paul J. ;
Sandborn, William J. ;
Yang, Mei ;
Camez, Anne ;
Pollack, Paul F. ;
Thakkar, Roopal B. ;
Robinson, Anne M. ;
Chen, Naijun ;
Mulani, Parvez M. ;
Chao, Jingdong .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (03) :414-+
[9]   Long-term evolution of disease behavior of Crohn's disease [J].
Cosnes, J ;
Cattan, S ;
Blain, A ;
Beaugerie, L ;
Carbonnel, F ;
Parc, R ;
Gendre, JP .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) :244-250
[10]   Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial [J].
Cosnes, Jacques ;
Bourrier, Anne ;
Laharie, David ;
Nahon, Stephane ;
Bouhnik, Yoram ;
Carbonnel, Franck ;
Allez, Matthieu ;
Dupas, Jean-Louis ;
Reimund, Jean-Marie ;
Savoye, Guillaume ;
Jouet, Pauline ;
Moreau, Jacques ;
Mary, Jean-Yves ;
Colombel, Jean-Frederic .
GASTROENTEROLOGY, 2013, 145 (04) :758-+